2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.

2.50
Hdl Handle:
http://hdl.handle.net/10029/621064
Title:
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.
Authors:
Rondy, Marc; Larrauri, Amparo; Casado, Itziar; Alfonsi, Valeria; Pitigoi, Daniela; Launay, Odile; Syrjänen, Ritva K; Gefenaite, Giedre; Machado, Ausenda; Vučina, Vesna Višekruna; Horváth, Judith Krisztina; Paradowska-Stankiewicz, Iwona; Marbus, Sierk D; Gherasim, Alin; Díaz-González, Jorge Alberto; Rizzo, Caterina; Ivanciuc, Alina E; Galtier, Florence; Ikonen, Niina; Mickiene, Aukse; Gomez, Veronica; Kurečić Filipović, Sanja; Ferenczi, Annamária; Korcinska, Monika R; van Gageldonk-Lafeber, Rianne; Valenciano, Marta
Abstract:
We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.
Citation:
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. 2017, 22 (30) Euro Surveill.
Journal:
Euro Surveill 2017, 22(30): pii:30580
Issue Date:
27-Jul-2017
URI:
http://hdl.handle.net/10029/621064
DOI:
10.2807/1560-7917.ES.2017.22.30.30580
PubMed ID:
28797322
Type:
Article
Language:
en
ISSN:
1560-7917
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorRondy, Marcen
dc.contributor.authorLarrauri, Amparoen
dc.contributor.authorCasado, Itziaren
dc.contributor.authorAlfonsi, Valeriaen
dc.contributor.authorPitigoi, Danielaen
dc.contributor.authorLaunay, Odileen
dc.contributor.authorSyrjänen, Ritva Ken
dc.contributor.authorGefenaite, Giedreen
dc.contributor.authorMachado, Ausendaen
dc.contributor.authorVučina, Vesna Višekrunaen
dc.contributor.authorHorváth, Judith Krisztinaen
dc.contributor.authorParadowska-Stankiewicz, Iwonaen
dc.contributor.authorMarbus, Sierk Den
dc.contributor.authorGherasim, Alinen
dc.contributor.authorDíaz-González, Jorge Albertoen
dc.contributor.authorRizzo, Caterinaen
dc.contributor.authorIvanciuc, Alina Een
dc.contributor.authorGaltier, Florenceen
dc.contributor.authorIkonen, Niinaen
dc.contributor.authorMickiene, Aukseen
dc.contributor.authorGomez, Veronicaen
dc.contributor.authorKurečić Filipović, Sanjaen
dc.contributor.authorFerenczi, Annamáriaen
dc.contributor.authorKorcinska, Monika Ren
dc.contributor.authorvan Gageldonk-Lafeber, Rianneen
dc.contributor.authorValenciano, Martaen
dc.date.accessioned2018-01-09T12:26:48Z-
dc.date.available2018-01-09T12:26:48Z-
dc.date.issued2017-07-27-
dc.identifier.citation2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. 2017, 22 (30) Euro Surveill.en
dc.identifier.issn1560-7917-
dc.identifier.pmid28797322-
dc.identifier.doi10.2807/1560-7917.ES.2017.22.30.30580-
dc.identifier.urihttp://hdl.handle.net/10029/621064-
dc.description.abstractWe conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.en
dc.language.isoenen
dc.rightsArchived with thanks to Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinen
dc.title2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.en
dc.typeArticleen
dc.identifier.journalEuro Surveill 2017, 22(30): pii:30580en

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.